The Risk Factors of Thrombosis in Patients with Philadelphia Chromosome-negative Myeloproliferative Neoplasms.
10.19746/j.cnki.issn.1009-2137.2021.06.030
- Author:
Yi-Fan ZHAO
1
;
Shao-Ze LIN
1
;
Xue BAI
1
;
Xue-Yang XING
1
;
Hong-Fang TAO
1
;
Yong-Zhong SU
2
Author Information
1. Department of Hematology， The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
2. Department of Hematology， The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China,E-mail：suyzst@126.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Myeloproliferative Disorders/genetics*;
Neoplasms;
Philadelphia Chromosome;
Risk Factors;
Thrombosis
- From:
Journal of Experimental Hematology
2021;29(6):1869-1874
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the overview of thrombosis in myeloproliferative neoplasms(MPN) patients, and to explore the risk factors of thrombosis at diagnosis and during follow-up.
METHODS:The clinical data of 388 MPN patients treated in our hospital were collected. The patients were followed up by outpatient and phone. The risk factors of thrombosis were analyzed by statistical methods.
RESULTS:Among 388 MPN patients, 161 patients (41.49%) showed thromboses at diagnosis or during follow-up. Among them, 92.55% were arterial thromboses, 146 cases (96.27%) were complicated with thromboses at diagnosis, and 36 cases (11.46%) showed newly thromboses or progression of previous thromboses among the 314 received full follow-up patients. Age (P＜0.001, HR:1.033, 95%CI:1.016-1.051), JAK2V617F mutation (P=0.037, HR:1.72, 95%CI: 1.033-2.862), hypertension (P＜0.001, HR:2.639, 95%CI:1.659-4.197) and hyperlipidemia (P＜0.001, HR:2.659, 95%CI:1.626-4.347) were the independent risk factors affecting thrombosis at diagnosis of the patients. During the follow-up, age (P=0.016, HR:1.032, 95%CI: 1.006-1.059) and previous thrombosis history (P=0.019, HR:2.194, 95%CI: 1.135-4.242) were the independent risk factors affecting the progression of thrombosis at different sites or on the basis of the previous thrombosis in the patients.
CONCLUSION:Patients with advanced age, JAK2V617F mutation or complicated with hypertension and hyperlipidemia shows a higher risk of thrombosis at diagnosis, while the patients with advanced age or previous thrombosis history shows a higher risk of progression of thrombosis during the follow-up.
